Cover Photo
American Journal of Pathology, February 180:819-830, 2012. (Photo)
Velagapudi C, Nilsson R-P, Barnes VL, Arar M, Abboud HE, Barnes JL. Reciprocal induction of simple organogenesis by mouse kidney progenitor cells in three-dimensional co-culture. Am J Pathol 180:819-830, 2012. (Cover Photo, February Issue). (CMMM-1 and CMUB-1: Mouse Kidney Primordial Cells)
NIH Grant Awards
NIH/NIEHS 43ES029879 SBIR Phase I. 09/01/18-08/31/19
Jeffrey L. Barnes, PhD, PI
3D Biomimetic Platforms to Model Kidney Cell Biology for In Vitro Toxicity Screening
NIEHS research initiative: “Organotypic Culture Models Developed from Experimental Animals for Chemical Toxicity Screening”
This $150,000 grant will aid the company in further developing its technology of 3-dimensional (3D) growth of mouse kidney medullary cells in vitro. Kidney primordial cells (ureteric bud and metanephric mesenchymal cells) reciprocally induce each other to develop into kidney organoids consisting of collecting duct epithelium surrounded by vascular structures. The organoids grown in 3D scaffolds in vitro will be used to assess nephrotoxicity of drugs and environmental chemicals that could have deleterious effects on kidney development and function. The technology may ultimately provide alternative methods to reduce the use of animals in toxicity testing.
NIH/NIGMS R41GM110837-01 SBIR Phase I. 08/15/14-08/14/15
Veronique L. Barnes, MD, PI
Kidney Progenitor Cells in Regenerative Medicine
Renal stem-cell technologies in treatment of renal disease are in their infancy. This application investigates the efficacy of metanephric mesenchymal, ureteric bud and glomerular progenitor embryonic kidney cell lines in cell-based therapy to treat acute kidney injury in rats. Rat kidney progenitor cell lines will be used to explore roles for cell integration and/or paracrine mechanisms in renal repair processes after injury. Determination of the efficacy of these cells to ameliorate kidney disease will foster further research in this important area of regenerative medicine. (Summary)
NIH/NIDDK R42DK077436-03 STTR Phase II. 8/15/09-6/30/12
Jeffrey L. Barnes, PhD, PI
Commercialization of Kidney Embryonic Cell Lines
The goal of this grant is to isolate and characterize new embryonic cell lines derived from the nephrogenic zone of embryonic metanephric kidney and establish a cell bank of kidney cell lines created during Phase I. Phase II will further characterize all newly developed cell lines. (Summary)
NIH/NIDDK R41DK077436-01 STTR Phase I. 08/1/07-7/31/08 (No cost extension to 1/31/09)
Jeffrey L. Barnes, PhD, PI
Commercialization of Kidney Embryonic Cell Lines
The goals of this project are to further characterize the differentiation potential of embryonic mesenchymal and ureteral bud cell lines derived from kidney primordia. A second specific aim is to isolate and characterize new embryonic cell lines derived from the nephrogenic zone of embryonic metanephric kidney and establish a cell bank of kidney cell lines created during Phase I. Phase II will further characterize all newly developed cell lines. (Summary)_
NIH/NIDDK R 43 DK061834-02 SBIR PhaseI II. 09/30/06-06/29/09
Veronique L. Barnes, MD PI
Tissue Products and Kits from Renal Disease
This Phase II grant focuses on large-scale production of reagents and tissue products (tissue sections, protein lysates, purified RNA, derived from the six models of kidney disease collectively representing the most common forms of renal disease presented clinically (i.e. mesangioproliferative glomerulonephritis, Crescentic anti-GBM disease, Membranous nephritis, Types 1 and 2 diabetic nephropathy and lupus nephritis). Also, the company will prepare and validate for commercialization seven kidney cell lines (glomerular mesangial, epithelial, and endothelial cells and embryonic stem cells) under the direction of Hanna Abboud, M.D. through a consortium agreement with UTHSCSA. (Summary)
NIH, NIDDK R 43 DK061834 SBIR Phase I. 05/14/04-04/30/05
Veronique L. Barnes, M.D. (PI)
Tissue Products and Kits from Renal Disease
The goals of this project were to validate antiserum and tissue products from three models of immune-mediated renal disease,(Anti-Thymocyte mesangioproliferative GN, Anti-GBM crecentic GN, Anti-FX1A ) Heymann antigen) membranous GN. To establish a plan for the subsequent expansion and commercialization of tissue products and services. In addition, a cell bank of six glomerular cell lines licensed to Probetex from UTHSCSA (mesangial, endothelial, and epithelial from various species) will be established. (Summary)
National Science Foundation
Role: Participating Company
Partnership for Innovation grant (2003) Awarded to SynreCom (Synergistic E-Commerce) in cooperation with the Electronic Commerce and Information Systems Department of the School of Business, Our Lady of the Lake University, TEKSA Innovations Corporation and participating companies. SynreCom is a unique blending of Texas resources to build intellect and confidence in underprivileged students in the community. The program offered these young adults technical skills, access to social services, and unlimited exposure and interaction with professionals. The students worked with the grantees and Probetex to design and launch the company’s first web site iteration.
American Journal of Pathology, February 180:819-830, 2012. (Photo)
Velagapudi C, Nilsson R-P, Barnes VL, Arar M, Abboud HE, Barnes JL. Reciprocal induction of simple organogenesis by mouse kidney progenitor cells in three-dimensional co-culture. Am J Pathol 180:819-830, 2012. (Cover Photo, February Issue). (CMMM-1 and CMUB-1: Mouse Kidney Primordial Cells)
NIH Grant Awards
NIH/NIEHS 43ES029879 SBIR Phase I. 09/01/18-08/31/19
Jeffrey L. Barnes, PhD, PI
3D Biomimetic Platforms to Model Kidney Cell Biology for In Vitro Toxicity Screening
NIEHS research initiative: “Organotypic Culture Models Developed from Experimental Animals for Chemical Toxicity Screening”
This $150,000 grant will aid the company in further developing its technology of 3-dimensional (3D) growth of mouse kidney medullary cells in vitro. Kidney primordial cells (ureteric bud and metanephric mesenchymal cells) reciprocally induce each other to develop into kidney organoids consisting of collecting duct epithelium surrounded by vascular structures. The organoids grown in 3D scaffolds in vitro will be used to assess nephrotoxicity of drugs and environmental chemicals that could have deleterious effects on kidney development and function. The technology may ultimately provide alternative methods to reduce the use of animals in toxicity testing.
NIH/NIGMS R41GM110837-01 SBIR Phase I. 08/15/14-08/14/15
Veronique L. Barnes, MD, PI
Kidney Progenitor Cells in Regenerative Medicine
Renal stem-cell technologies in treatment of renal disease are in their infancy. This application investigates the efficacy of metanephric mesenchymal, ureteric bud and glomerular progenitor embryonic kidney cell lines in cell-based therapy to treat acute kidney injury in rats. Rat kidney progenitor cell lines will be used to explore roles for cell integration and/or paracrine mechanisms in renal repair processes after injury. Determination of the efficacy of these cells to ameliorate kidney disease will foster further research in this important area of regenerative medicine. (Summary)
NIH/NIDDK R42DK077436-03 STTR Phase II. 8/15/09-6/30/12
Jeffrey L. Barnes, PhD, PI
Commercialization of Kidney Embryonic Cell Lines
The goal of this grant is to isolate and characterize new embryonic cell lines derived from the nephrogenic zone of embryonic metanephric kidney and establish a cell bank of kidney cell lines created during Phase I. Phase II will further characterize all newly developed cell lines. (Summary)
NIH/NIDDK R41DK077436-01 STTR Phase I. 08/1/07-7/31/08 (No cost extension to 1/31/09)
Jeffrey L. Barnes, PhD, PI
Commercialization of Kidney Embryonic Cell Lines
The goals of this project are to further characterize the differentiation potential of embryonic mesenchymal and ureteral bud cell lines derived from kidney primordia. A second specific aim is to isolate and characterize new embryonic cell lines derived from the nephrogenic zone of embryonic metanephric kidney and establish a cell bank of kidney cell lines created during Phase I. Phase II will further characterize all newly developed cell lines. (Summary)_
NIH/NIDDK R 43 DK061834-02 SBIR PhaseI II. 09/30/06-06/29/09
Veronique L. Barnes, MD PI
Tissue Products and Kits from Renal Disease
This Phase II grant focuses on large-scale production of reagents and tissue products (tissue sections, protein lysates, purified RNA, derived from the six models of kidney disease collectively representing the most common forms of renal disease presented clinically (i.e. mesangioproliferative glomerulonephritis, Crescentic anti-GBM disease, Membranous nephritis, Types 1 and 2 diabetic nephropathy and lupus nephritis). Also, the company will prepare and validate for commercialization seven kidney cell lines (glomerular mesangial, epithelial, and endothelial cells and embryonic stem cells) under the direction of Hanna Abboud, M.D. through a consortium agreement with UTHSCSA. (Summary)
NIH, NIDDK R 43 DK061834 SBIR Phase I. 05/14/04-04/30/05
Veronique L. Barnes, M.D. (PI)
Tissue Products and Kits from Renal Disease
The goals of this project were to validate antiserum and tissue products from three models of immune-mediated renal disease,(Anti-Thymocyte mesangioproliferative GN, Anti-GBM crecentic GN, Anti-FX1A ) Heymann antigen) membranous GN. To establish a plan for the subsequent expansion and commercialization of tissue products and services. In addition, a cell bank of six glomerular cell lines licensed to Probetex from UTHSCSA (mesangial, endothelial, and epithelial from various species) will be established. (Summary)
National Science Foundation
Role: Participating Company
Partnership for Innovation grant (2003) Awarded to SynreCom (Synergistic E-Commerce) in cooperation with the Electronic Commerce and Information Systems Department of the School of Business, Our Lady of the Lake University, TEKSA Innovations Corporation and participating companies. SynreCom is a unique blending of Texas resources to build intellect and confidence in underprivileged students in the community. The program offered these young adults technical skills, access to social services, and unlimited exposure and interaction with professionals. The students worked with the grantees and Probetex to design and launch the company’s first web site iteration.